Hepatopulmonary syndrome David G. Koch a and Michael B. Fallon b
Purpose of review To discuss the advances in the understanding of the pathophysiology of experimental and human hepatopulmonary syndrome (HPS) and in the management of HPS, particularly regarding liver transplantation. Recent findings Advances have been made in defining the pathophysiology of HPS in experimental models as well as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis. Additionally, the implications of the presence of HPS as it relates to prioritizing patients for liver transplantation and posttransplant outcomes will also be reviewed. Summary Mechanisms of disease continue to be defined in HPS, providing potential targets for pharmacologic intervention. Outcomes after liver transplantation are also becoming clearer, including the management of HPS with severe hypoxemia. Keywords hepatopulmonary syndrome, hypoxemia, intrapulmonary vasodilatation, liver transplantation, portal hypertension
INTRODUCTION The hepatopulmonary syndrome (HPS) is a pulmonary complication that occurs in patients with chronic liver disease and/or portal hypertension, whereby hypoxemia results from alterations in the pulmonary microvasculature, including vasodilatation and angiogenesis. HPS is relatively common, occurring in up to 30% of patients with cirrhosis [1,2]. Although the degree of hypoxemia in HPS does not reliably correlate with the severity of liver disease, patients with HPS have increased mortality relative to cirrhosis patients without HPS. The diagnostic criteria for HPS include documentation of impaired oxygenation and intrapulmonary vasodilatation (IPVD) in the setting of chronic liver disease or portal hypertension  (see list below). Oxygenation in HPS is determined by calculating the alveolar–arterial oxygen gradient (AapO2) from an arterial blood gas (ABG); a threshold of greater than 15 mmHg is used except for patients older than age 64, in whom greater than 20 mmHg is appropriate. Therefore, patients with mild HPS may not have hypoxemia. The syndrome may occur in patients with comorbid primary lung diseases [4,5], and having cirrhosis is not imperative as HPS has been described in acute and chronic hepatitis without cirrhosis or portal hypertension www.co-gastroenterology.com
[6,7] as well as in noncirrhotic portal hypertension without chronic liver disease [8–11]. Much of our knowledge of the pathophysiology of HPS is based on a unique experimental model, common bile duct ligation (CBDL), which recreates the features of human HPS. Although progress has been made in defining the mechanisms underlying the pulmonary vascular changes in HPS, to date, there are no approved therapeutic options aside from liver transplantation. Diagnostic criteria for the HPS are as follows: (1) increased age-corrected alveolar–arterial oxygen gradient (>15 mmHg or >20 mmHg if age >64 years) while breathing ambient air: a
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina and bDivision of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA Correspondence to David G. Koch, MD, MSCR, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of South Carolina, 25 Courtenay Drive, ART 7100A, MSC 290, Charleston, SC 29425, USA. Tel: +1 843 792 6901; fax: +1 843 876 4301; e-mail: [email protected] Curr Opin Gastroenterol 2014, 30:260–264 DOI:10.1097/MOG.0000000000000067 Volume 30 Number 3 May 2014
AapO2 ¼ [FiO2(Patm –pH2O)–( pCO2/0.8)] – PaO2, in which PaO2 is the partial pressure of arterial oxygen; FiO2 is the fraction of inspired oxygen; Patm is the atmospheric pressure; pH2O is the partial pressure of water vapor at body temperature; and paCO2 is the partial pressure of arterial carbon dioxide (0.8 corresponds to the standard gas-exchange respiratory ratio at rest); (2) positive contrast-enhanced echocardiography or lung-perfusion scanning (brain shunt fraction >6%); (3) cirrhosis and/or portal hypertension.
correlated with the degree of bile duct proliferation in the corresponding liver biopsy specimens [26 ]. However, whether proliferating cholangiocytes in human cirrhosis produce and secrete ET-1 thereby raising the blood levels is still not known. A causal relationship between ET-1 and impairment in oxygenation in HPS that would support pharmacologic manipulation of the ET-1 and ETB receptor axis has also not been established. In addition to the role of ET-1 in experimental and human HPS, recent studies in experimental HPS have furthered our understanding of other pathways that contribute to the underlying pulmonary vascular phenomena. These include the roles of pulmonary intravascular monocytes [27 ], TNF-a , and angiogenesis [27 ,29 ] as well as the therapeutic utility in manipulating these pathways in order to improve oxygenation. The ability of serum from CBDL rats with HPS to induce a proliferative effect on pulmonary artery smooth muscle cells (PASMCs) and pulmonary microvascular endothelial cells (PMVECs) is also being understood. With respect to intrapulmonary monocytes, it is known that these cells accumulate in the lung vasculature after CBDL and that they contribute to IPVD by increasing the levels of nitric oxide [via inducible nitric oxide synthase (iNOS)] and carbon monoxide [via heme oxygenase-1 (HO-1)]. More recently, it has been demonstrated that the adherence of monocytes is regulated through ET-1 and ETB receptor activation which increases the levels of the monocyte chemokine, fractalkine (FKN/CX3CL1–CX3CR1). FKN induces pulmonary monocyte adhesion and also promotes angiogenesis directly and through monocyte secretion of vascular endothelial growth factor-A (VEGF-A) [27 ]. VEGF-A is also produced in the CBDL liver and induces cholangiocyte proliferation through extracellular-signal-regulated kinase (ERK) activation [30 ]. Furthermore, inhibiting the effects of VEGF-A with the receptor tyrosine kinase inhibitor, sorafenib, improves oxygenation in experimental HPS [29 ,30 ] by reducing pulmonary monocyte adhesion and subsequent VEGF-A production as well as by blocking cholangiocyte proliferation in the liver through inhibition of ERK activation [30 ]. Whether sorafenib has similar effects on cholangiocytes in human HPS and may improve hypoxemia is not known. However, the potential to manipulate this pathway pharmacologically in patients with HPS is attractive as sorafenib is approved for use in humans with cirrhosis. At the cellular level, serum from CBDL rats induces the proliferation of both PMVECs and PASMCs, effects that could contribute to lung angiogenesis and remodeling in HPS. CBDL serum &
The CBDL experimental model recreates the features of human HPS [12–20] (Fig. 1). In this model, proliferating cholangiocytes in the liver produce and secrete endothelin-1 (ET-1) [12–16], whereas other models of portal hypertension that do not result in bile duct proliferation do not develop HPS . Increased shear stress in the pulmonary microvasculature, as a result of a hyperdynamic circulation of cirrhosis, results in upregulation of the endothelin B (ETB) receptor that subsequently binds the increased circulating ET-1 and augments pulmonary nitric oxide production via endothelial nitric oxide synthase (eNOS) [12,15,19,21–25]. The potential role of biliary ET-1 in human HPS was shown in a single study, in which hepatic venous blood levels of ET-1 were higher in cirrhosis patients with IPVD and HPS compared with those without IPVD. In addition, the hepatic venous ET-1 levels in these patients
Liver Cholangiocyte ET-1
Endothelial Cell Vasodilatation
FIGURE 1. Mechanisms of hypoxemia in the common bile duct ligation model of HPS. CO, carbon monoxide; ET-1, endothelin-1; ETBR, endothelin B receptor; HO-1, heme oxygenase-1; HPS, hepatopulmonary syndrome; iNOS, inducible nitric oxide synthase; NO, nitric oxide; p-eNOS, phosphorylated endothelial nitric oxide synthase; VEGF-A, vascular endothelial growth factor A.
0267-1379 ß 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
increased the cytoskeleton proteins within PMVECs cells and promoted proliferation by decreasing the expression levels of Annexin A1, a Ca[2þ]-dependent phospholipid-binding protein . Conversely, CBDL serum upregulates Annexin A2, promoting PASMC proliferation . Either promoting Annexin A1 expression or inhibiting Annexin A2 was found to ameliorate hypoxemia in experimental HPS [31,32]. Finally, new insights into how bacterial translocation and endotoxemia drive inflammation in experimental HPS have been made. Evidence of endoplasmic reticulum stress as evidenced by increased lung levels of 78 kDa glucose-regulated protein are found after CBDL. This protein, in turn, has a strong, positive correlation with the blood levels of endotoxin and TNF-a. Prophylactic levofloxacin prevented pulmonary airway and vascular remodeling after CBDL, in association with lowering glucose-regulated protein levels, presumably by limiting bacterial translocation and inflammation . The confirmation that TNF-a is implicated in experimental HPS was also achieved by ameliorating hypoxemia with a TNF-a monoclonal antibody . The CBDL model has provided a platform to study the mechanisms that underlie IPVD and HPS. The progress that has been made in defining the importance of inflammation, pulmonary angiogenesis, and vascular remodeling in experimental HPS may provide additional targets that can be manipulated therapeutically in humans, thereby increasing our treatment options beyond liver transplantation.
HUMAN DISEASE Although pharmacologic interventions to improve oxygenation in patients with HPS are currently lacking, two recent reports have shown potential benefit with pentoxifylline [34 ] and mycophenolate mofetil . Although prior studies have shown conflicting results regarding the ability of pentoxifylline to improve oxygenation (attributed to poor tolerability from gastrointestinal side-effects), the current report did show benefit in six of ten children with HPS who were able to tolerate the medication. These six children had an average increase in PaO2 of 26 mmHg, which then diminished after the treatment was held. All children experienced nausea and vomiting, which was the cause for three of the four children who did not tolerate treatment to discontinue its use. In addition to this small pilot study, a case was reported documenting the resolution of HPS with mycophenolate mofetil in a teenage boy with noncirrhotic portal hypertension , raising the possibility of its therapeutic benefit. The authors &
postulated that the antiangiogenic effects of mycophenolate mofetil may have been the reason for improved oxygenation. However, the established ability of mycophenolate mofetil to inhibit endothelial cell production of ET-1 and also reduce nitric oxide may have also contributed to the observed therapeutic effect. Despite these small reports of therapeutic options and advancements that have been made in understanding the pathophysiology of HPS in the CBDL model, liver transplantation remains the only therapeutic option that can reliably improve oxygenation and survival in humans [36,37,38 ]. However, there has been continued interest in evaluating the effects of lowering portal pressure with transjugular intrahepatic shunt (TIPS) in patients with HPS [39–47]. Two recent cases of TIPS improving oxygenation in HPS have been published [48,49], increasing the number of reported cases to nine. However, similar to the pharmacologic therapies, TIPS has not been consistently beneficial in HPS, and the short duration of the follow-up reported makes it difficult to know whether TIPS is a reliable treatment option. Given the potential risk for hepatic decompensation and encephalopathy after TIPS placement and the relative lack of published data confirming utility, TIPS is not currently recommended to treat HPS. However, TIPS does not appear to worsen oxygenation in HPS, so it is generally considered as a reasonable option to manage comorbid refractory ascites and variceal bleeding in patients with established HPS. As severe HPS may occur in those with preserved hepatic synthetic function and adversely influence survival, patients with advanced disease (PaO2 <60 mmHg) deemed acceptable for liver transplantation are eligible for model of end-stage liver disease (MELD) exception points to make them competitive for an organ on the waitlist. Patients who receive HPS MELD exception have better preliver transplantation survival than those without HPS and appear to have similar postliver transplantation outcomes to those without HPS [38 ,50 ]. The largest single-center experience with liver transplantation for HPS also found, in contrast to the prior reports, that very severe hypoxemia (PaO2 <50 mmHg while breathing ambient air) did not appear to compromise liver transplantation outcomes [38 ,50 ]. However, a recent comprehensive analysis of all United Network for Organ Sharing (UNOS) data on MELD exception for HPS demonstrates that HPS patients with a PaO2 less than 44 mmHg are at increased risk for postliver transplantation mortality [50 ]. Additionally, patients with an HPS MELD exception had lower waitlist mortality than those without an HPS exception. These studies support a MELD exception policy &&
for HPS but provide new data which suggest that the current policy for applying HPS MELD exceptions may need modification to achieve excellent and equitable outcomes for patients undergoing liver transplantation by not placing HPS patients at an advantage.
CONCLUSION HPS is a common complication of cirrhosis that results from alterations in the pulmonary microvasculature. Progress continues to be made in defining the mechanisms of hypoxemia in experimental HPS that recreates the features of human HPS, particularly regarding the roles of inflammation (intrapulmonary monocytes and TNF-a) as well as angiogenesis. The pathophysiology of HPS, conversely, is not clearly defined in humans, and this has limited our discovery of pharmacologic agents that could reverse the underlying process and improve oxygenation. Therefore, liver transplantation remains the only reliable treatment option. MELD exception for HPS has resulted in similar postliver transplantation outcomes in those with HPS MELD exception relative to those without HPS. However, preliver transplantation survival is better in those with HPS MELD exception relative to others and those with very severe HPS (PaO2 <44 mmHg) have increased mortality. These findings support that modification of the MELD exception for HPS may be appropriate to optimize outcomes for all patients waiting for liver transplantation. Acknowledgements Financial disclosures: None. Conflicts of interest There are no conflicts of interest.
REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest && of outstanding interest 1. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109:1283–1288. 2. Schenk P, Fuhrmann V, Madl C, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51:853–859. 3. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary–hepatic vascular disorders (PHD). Eur Respir J 2004; 24:861–880. 4. Abrams GA, Nanda NC, Dubovsky EV, et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114:305–310. 5. Martinez G, Barbera JA, Navasa M, et al. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999; 30:882–889. 6. Regev A, Yeshurun M, Rodriguez M, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat 2001; 8:83– 86.
7. Teuber G, Teupe C, Dietrich CF, et al. Pulmonary dysfunction in noncirrhotic patients with chronic viral hepatitis. Eur J Intern Med 2002; 13:311–318. 8. Sari S, Oguz D, Sucak T, et al. Hepatopulmonary syndrome in children with cirrhotic and noncirrhotic portal hypertension: a single-center experience. Dig Dis Sci 2012; 57:175–181. 9. Gupta D, Vijaya DR, Gupta R, et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001; 96:3395–3399. 10. De BK, Sen S, Biswas PK, et al. Occurrence of hepatopulmonary syndrome in Budd–Chiari syndrome and the role of venous decompression. Gastroenterology 2002; 122:897–903. 11. Krowka MJ. Hepatopulmonary syndrome and extrahepatic vascular abnormalities. Liver Transpl 2001; 7:656–657. 12. Fallon MB, Abrams GA, Luo B, et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997; 113:606–614. 13. Fallon MB, Abrams GA, McGrath JW, et al. Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol 1997; 272:G779–G784. 14. Zhang J, Ling Y, Luo B, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology 2003; 125:1441–1451. 15. Zhang M, Luo B, Chen SJ, et al. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol 1999; 277:G944–G952. 16. Zhang X, Katsuta Y, Akimoto T, et al. Intrapulomnary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct dilation. J Hepatol 2003; 39:724–730. 17. Katsuta Y, Zhang XJ, Ohsuga M, et al. Arterial hypoxemia and intrapulmonary vasodilatation in rat models of portal hypertension. J Gastroenterol 2005; 40:811–819. 18. Lee KN, Yoon SK, Lee JW, et al. Hepatopulmonary syndrome induced by common bile duct ligation in a rabbit model: correlation between pulmonary vascular dilatation on thin-section CT and angiography and serum nitrite concentration or endothelial nitric oxide synthase (eNOS)1 expression. Korean J Radiol 2004; 5:149–156. 19. Liu M, Tian D, Wang T, et al. Correlation between pulmonary endothelin receptors and alveolar–arterial oxygen gradient in rats with hepatopulmonary syndrome. J Huazhong Univ Sci Technol Med Sci 2005; 25:494–496. 20. Zhang XJ, Katsuta Y, Akimoto T, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol 2003; 39:724–730. 21. Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 2004; 39:1593–1602. 22. Luo B, Abrams GA, Fallon MB. Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. J Hepatol 1998; 29:571–578. 23. Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003; 38:556–563. 24. Luo B, Tang L, Wang Z, et al. Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005; 129:682–695. 25. Luo B, Tang L, Zhang J, et al. Biliary epithelium derived endothelin-1: an endocrine mediator of experimental hepatopulmonary syndrome. Hepatology 2004; 40:214A. 26. Koch DG, Bogatkevich G, Ramshesh V, et al. Elevated levels of endothelin-1 & in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci 2012; 57:516–523. This study provides evidence that ET-1 may have a role in the pathophysiology of human HPS. 27. Zhang J, Yang W, Luo B, et al. The role of CX(3)CL1/CX(3)CR1 in pulmonary && angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. J Hepatol 2012; 57:752–758. This study defines the relationship between ET-1, pulmonary monocytes, and angiogenesis in experimental HPS. 28. Liu L, Liu N, Zhao Z, et al. TNF-alpha neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int 2012; 32:1018–1026. 29. Chang CC, Chuang CL, Lee FY, et al. Sorafenib treatment improves hepa&& topulmonary syndrome in rats with biliary cirrhosis. Clin Sci (Lond) 2013; 124:457–466. This study demonstrates that the antiangiogenic agent, sorafenib, improves oxygenation in experimental HPS. 30. Yang W, Zhang J, Hu B, et al. The role of receptor tyrosine kinase activation in && cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. Am J Physiol Gastrointest Liver Physiol 2014; 306:G72–G80. This study confirms the benefit of sorafenib in experimental HPS and explores the novel mechanism that tyrosine kinase inhibition diminishes BDP in the liver. 31. Yi B, Zeng J, Wang G, et al. Annexin A1 protein regulates the expression of PMVEC cytoskeletal proteins in CBDL rat serum-induced pulmonary microvascular remodeling. J Transl Med 2013; 11:98.
0267-1379 ß 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
Liver 32. Zeng J, Yi B, Wang Z, et al. Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation of pulmonary arterial smooth muscle cells. Respir Physiol Neurobiol 2013; 185:332–338. 33. Gaio E, Amado V, Rangel L, et al. Levofloxacin decreased chest wall mechanical inhomogeneities and airway and vascular remodeling in rats with induced hepatopulmonary syndrome. Respir Physiol Neurobiol 2013; 189:565–570. 34. Kianifar HR, Khalesi M, Mahmoodi E, Afzal Aghaei M. Pentoxifylline in & hepatopulmonary syndrome. World J Gastroenterol 2012; 18:4912–4916. This pilot study shows the potential benefit of pentoxifylline in humans with HPS who can tolerate the medication. 35. Moreira Silva H, Reis G, Guedes M, et al. A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production). J Hepatol 2013; 58:630–633. 36. Gupta S, Castel H, Rao RV, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant 2010; 10:354– 363. 37. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005; 41:1122–1129. 38. Iyer VN, Swanson KL, Cartin-Ceba R, et al. Hepatopulmonary syndrome: && favorable outcomes in the MELD exception era. Hepatology 2013; 57:2427– 2435. This study is the largest series documenting the posttransplant outcomes in patients with HPS, the potential benefit of the MELD exception policy for HPS, and the acceptable survival in those with severe hypoxemia. 39. Corley DA, Scharschmidt B, Bass N, et al. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology 1997; 113:728–730. 40. Allgaier HP, Haag K, Ochs A, et al. Hepato-pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 1995; 23:102. 41. Benitez C, Arrese M, Jorquera J, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. Ann Hepatol 2009; 8:71–74.
42. Chevallier P, Novelli L, Motamedi JP, et al. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 2004; 15:647–648. 43. Paramesh AS, Husain SZ, Shneider B, et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant 2003; 7:157–162. 44. Lasch HM, Fried MW, Zacks SL, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 2001; 7:147–149. 45. Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858–6862. 46. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995; 109:978–983. 47. Selim KM, Akriviadis EA, Zuckerman E, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998; 93:455–458. 48. Nistal MW, Pace A, Klose H, et al. Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt. Thorax 2013; 68:889–890. 49. Wallace MC, James AL, Marshall M, Kontorinis N. Resolution of severe hepato-pulmonary syndrome following transjugular portosystemic shunt procedure. BMJ Case Rep 2012; 2012:. 50. Goldberg DS, Krok K, Batra S, et al. Impact of the hepatopulmonary && syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology 2014. (In press). This study analyzed pretransplant and posttransplant outcomes of HPS patients in the United States and identified a room-air PaO2 of 44 mmHg or less as a threshold for increased posttransplant mortality.
The hepatopulmonary syndrome has been acknowledged as an important vascular complication in lungs developing systemic hypoxemia in patients with cirrhosis and portal hypertension. Is formed by arterial oxygenation abnormalities induced from intrapulm
We report the case of a 52-year-old female, a known case of Chronic Liver Disease with portal hypertension. She presented with dyspnoea, platypnoea, melena, cyanosis, clubbing and orthodeoxia. She had oesophageal varices and splenomegaly indicating p
Portopulmonary hypertension (POPH) and hepatopulmonary syndrome (HPS) are two frequent complications of liver disease, with prevalence among liver transplant candidates of 6% and 10%, respectively. Both conditions result from a lack of hepatic cleara
Hepatopulmonary Syndrome (HPS) is a potential complication of chronic liver disease and is more commonly seen in the adult population. Caroli Syndrome is a rare inherited disorder characterized by intrahepatic ductal dilation and liver fibrosis that
Leishmaniasis caused by Leishmania infantum is endemic in the Mediterranean region. Its visceral form can present a diagnostic challenge owing to the disease's wide spectrum of clinical presentations. We describe the very atypical case of a 66-year-o
In a previous small retrospective study, the authors reported that hepatopulmonary syndrome was less common among liver transplant candidates at high-altitude centres compared with low-altitude centres.
Regarding a patient with dyspnea, the history and physical examination often lead to the correct diagnosis. In some circumstances, when more than one underlying disease is present, the diagnostic process can be more challenging. We describe an unusua
Hepatopulmonary syndrome (HPS) is defined as an oxygenation defect induced by intrapulmonary vasodilation in patients with liver disease or portal hypertension. It is investigated in patients with liver cirrhosis and less frequently in those with por